Manufactures specialty chemicals across three core segments — Home Care, Personal Care & Pharma Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health & Nutrition (AHN) — serving B2B customers in home care, personal care, pharma, textiles, agrochemicals, performance chemicals and animal nutrition. Runs two manufacturing plants at Silvassa and Dahej, with subsidiary Unitop Chemicals providing ethoxylation capacity, and has commissioned a new 5,000 MTPA blending facility in Thailand for Southeast Asian markets. A greenfield project in Saudi Arabia is in progress, with management indicating about 1.5 years from announcement to first kilo of production. Customers in 50+ countries are served, with a dedicated R&D centre in Navi Mumbai supporting an innovation pipeline of biosurfactants, NMMO, MDEA, spray-cooled powders and pharma formulations. The B2C consumer business is being exited while institutional cleaning is retained, with a steady-state 15% EBITDA margin targeted over 2-3 years via product-mix upgrade. Raw materials — primarily ethylene oxide and phenol — are the largest cost at 66.9% of revenue, while the Andheri office was sold and net debt reduced to Rs. 248 crore in Q1 FY27. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Home Care, Personal Care & Pharma Chemicals (HPPC), Textile Specialty Chemicals (TSC), Animal Health & Nutrition (AHN), Institutional cleaning. Cyclical, raw-material-intensive specialty chemicals manufacturer with three segments and ongoing international expansion
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 |
| EBITDA (ex other income) | 183 | 223 | 250 | 265 | 286 |
| margin % | 12.4 | 13.5 | 13.6 | 12.7 | 11.9 |
| Owners' profit | 98 | 107 | 131 | 136 | 149 |
| EPS, as reported (₹) | 17.81 | 19.46 | 23.67 | 24.66 | 26.95 |
| ROE % · ROCE % | 12.1 · 15.3 | 11.7 · 16.2 | 12.5 · 17.2 | 11.5 · 14.9 | 11.2 · 15.3 |
| Debt / equity (x) | 0.01 | 0.08 | 0.10 | 0.16 | 0.31 |
| Cash from operations | 29 | 152 | 43 | 137 | 65 |
| Capex | (38) | (33) | (131) | (159) | (265) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 498 | 513 | 580 | 544 | 586 | 582 | 685 | 697 |
| Profit before tax | 48 | 42 | 48 | 46 | 49 | 42 | 64 | 47 |
| Net profit | 35 | 32 | 34 | 34 | 37 | 33 | 46 | 35 |
| EPS (₹) | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 | 5.92 | 8.30 | 6.34 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Investor and analyst meet scheduled for September 17, 2026 in Mumbai | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Rossari Biotech to skip investor conference on August 10, 2026 | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Rossari Biotech to skip Nirmal Bang investor conference on Aug 10, 2026 | board shareholder meetings | low | — | — |
| 3 Aug 2026 · Rossari Biotech to attend Nirmal Bang investor conference on Aug 10 | board shareholder meetings | low | — | — |
| 3 Aug 2026 · Rossari Biotech schedules analyst and institutional investor meeting | board shareholder meetings | low | — | — |
| 24 Jul 2026 · Q1 FY27 call transcript: revenue up 28% YoY, guides for 15% steady-state EBITDA margin | investor communications | medium | — | — |
| 20 Jul 2026 · Rossari Biotech AGM: All 8 resolutions passed, Re 0.50 dividend declared | board shareholder meetings | low | — | — |
| 20 Jul 2026 · Audio recording of Q1 FY27 earnings call available on website | investor communications | low | — | — |
| 20 Jul 2026 · Correction: ESOP 2019 options granted revised to 5,000 | capital market events | low | — | — |
| 19 Jul 2026 · Rossari Biotech Q1 FY27: Revenue up 28% YoY to record Rs. 697.2 cr | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| AETHER INDUSTRIES LIMITED | 22,229 | 94.3 | 9.05 | 60.4 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 16.5 | 23.4 | 29 of 103 | 73% |
| P/B | 1.9 | 2.9 | 33 of 99 | 67% |
| ROCE | 13.4 | 10.3 | 40 of 108 | 64% |
| ROE | 11.2 | 8.1 | 40 of 101 | 61% |
| Debt / Equity | 0.3 | 0.2 | 67 of 101 | 34% |
| EBITDA margin | 12.0 | 15.5 | 66 of 99 | 34% |
| Revenue growth | 28.2 | 24.4 | 37 of 94 | 61% |
| Profit growth | 4.5 | 55.1 | 71 of 92 | 23% |
| Market cap | 2481 | 732 | 35 of 107 | 68% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
